ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.10, Bloomberg Earnings reports. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The business had revenue of $35.58 million for the quarter, compared to the consensus estimate of $32.03 million. During the same quarter last year, the firm posted ($0.61) EPS. The company’s revenue for the quarter was up 571.3% on a year-over-year basis.
ACADIA Pharmaceuticals (NASDAQ ACAD) traded up $0.80 on Thursday, hitting $27.64. 1,582,644 shares of the company traded hands, compared to its average volume of 1,680,759. ACADIA Pharmaceuticals has a 1 year low of $24.31 and a 1 year high of $41.20.
ILLEGAL ACTIVITY WARNING: “ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Announces Earnings Results” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/11/16/acadia-pharmaceuticals-inc-acad-issues-quarterly-earnings-results-beats-estimates-by-0-10-eps.html.
In related news, EVP Glenn Baity sold 37,500 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $40.91, for a total value of $1,534,125.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 22.25% of the company’s stock.
A number of research analysts have recently issued reports on the stock. ValuEngine raised shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 10th. Cowen and Company reaffirmed an “outperform” rating and issued a $46.00 price objective (up previously from $42.00) on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 10th. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $34.00 price objective on the stock in a research report on Friday, August 11th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $54.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the company. ACADIA Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $47.44.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.